159 research outputs found
Final implementation, commissioning, and performance of embedded collimator beam position monitors in the Large Hadron Collider
During Long Shutdown 1, 18 Large Hadron Collider (LHC) collimators were replaced with a new
design, in which beam position monitor (BPM) pick-up buttons are embedded in the collimator jaws.
The BPMs provide a direct measurement of the beam orbit at the collimators, and therefore can be used to
align the collimators more quickly than using the standard technique which relies on feedback from beam
losses. Online orbit measurements also allow for reducing operational margins in the collimation hierarchy
placed specifically to cater for unknown orbit drifts, therefore decreasing the β and increasing the
luminosity reach of the LHC. In this paper, the results from the commissioning of the embedded BPMs
in the LHC are presented. The data acquisition and control software architectures are reviewed.
A comparison with the standard alignment technique is provided, together with a fill-to-fill analysis of
the measured orbit in different machine modes, which will also be used to determine suitable beam
interlocks for a tighter collimation hierarchy.peer-reviewe
Mental health in pregnant individuals during the COVID-19 pandemic based on a Swiss online survey.
The aim of our study was to evaluate the mental health of pregnant individuals during the early COVID-19 pandemic and the potential factors associated. A Swiss online survey was proposed to individuals who gave birth during the pandemic period from March 2020. The Edinburgh Postnatal Depression Scale (EPDS), Generalized Anxiety Disorder 7 questions (GAD-7), and Impact Event Scale-Revised (IES-R) were evaluated and used to defined mental health impairment as a composite outcome. From October, 2020 to February, 2021, 736 participants responded. The anxiety GAD-7 score was moderate in 9.6% and severe in 2.0%. The EPDS was moderate in 21.5% and severe in 32.9%. The IES-R was moderate in 10.3% and severe in 3.9%. Mental health impairment was reported in 37.0%. The association between the risk of mental health impairment and foreign nationality was significant (OR = 1.48; 95%CI [1.06-2.05]) as well as fetal and pregnancy worries because of coronavirus (OR = 1.46; 95% CI [1.08-1.98]) and 1.65; 95% CI [1.22-2.24]). Adjusted ORs were significant for foreign nationality (aOR = 1.51; 95%CI [1.07-2.13]) and pregnancy worries because of coronavirus (aOR = 1.62; 95%CI [1.10-2.40]). Pregnant people and especially foreign national have a high risk of mental health impairment during the pandemic
TCT-255 Favourable Long-term Survival Of Out-of-hospital Cardiac Arrest Patients Managed With Systematic Coronary Angiogram On Admission
First operational experience with the LHC Diode ORbit and OScillation (DOROS) System
The LHC started high-energy operation in 2015 with
new tertiary collimators, equipped with beam position
monitors embedded in their jaws. The required resolution
and stability of the beam orbit measurements linked to
these BPMs were addressed by the development of a new
Diode ORbit and OScillation (DOROS) system. DOROS
converts the short BPM electrode pulses into slowly
varying signals by compensated diode detectors, whose
output signals can be precisely processed and acquired
with 24-bit ADCs. This scheme allows a sub-micrometre
orbit resolution to be achieved with robust and relatively
simple hardware. The DOROS system is also equipped
with dedicated channels optimised for processing beam
oscillation signals. Data from these channels can be used
to perform betatron coupling and beta-beating
measurements. The achieved performance of the DOROS
system triggered its installation on the beam position
monitors located next to the LHC experiments for testing
the system as an option of improving the beam orbit
measurement in the most important LHC locations. After
introducing the DOROS system, its performance is
discussed through both, beam and laboratory
measurements.peer-reviewe
Determinants of Vaccination and Willingness to Vaccinate against COVID-19 among Pregnant and Postpartum Women during the Third Wave of the Pandemic: A European Multinational Cross-Sectional Survey.
With COVID-19 vaccination hesitancy at around 50% in the obstetric population, it is critical to identify which women should be addressed and how. Our study aimed to assess COVID-19 vaccination willingness among pregnant and postpartum women in Europe and to investigate associated determinants. This study was a cross-sectional, web-based survey conducted in Belgium, Norway, Switzerland, The Netherlands, and United Kingdom (UK) in June-August 2021. Among 3194 pregnant women, the proportions of women vaccinated or willing to be vaccinated ranged from 80.5% in Belgium to 21.5% in Norway. The associated characteristics were country of residence, chronic illness, history of flu vaccine, trimester of pregnancy, belief that COVID-19 is more severe during pregnancy, and belief that the COVID-19 vaccine is effective and safe during pregnancy. Among 1659 postpartum women, the proportions of women vaccinated or willing to be vaccinated ranged from 86.0% in the UK to 58.6% in Switzerland. The associated determinants were country of residence, chronic illness, history of flu vaccine, breastfeeding, and belief that the COVID-19 vaccine is safe during breastfeeding. Vaccine hesitancy in the obstetric population depends on medical history and especially on the opinion that the vaccine is safe and on the country of residence
DESIRE: Leveraging the best of centralized and decentralized contact tracing systems
International audienceContact tracing in case of pandemic is becoming an essential mitigation tool for national health services to break infection chains and prevent the virus from spreading further. To support manual tracing, several countries have been developing contact tracing apps that detect nearby mobile phones using Bluetooth. Such data collection raised privacy concerns and several privacy-preserving protocols have been proposed to prevent the leakage of personal and sensitive information. These solutions are mainly divided into two categories using a centralized or a decentralized exposure score computation. However, both approaches depict limitations. This paper presents Desire, a novel exposure notification system which leverages the best of centralized and decentralized systems. As opposed to existing contact tracing schemes, Desire leverages Private Encounter Tokens (Pets) generated locally on the device that uniquely identify an encounter between two nodes while being private and unlinkable by the server. The role of the server is merely to match PETs generated by diagnosed users with the pets provided by requesting users. Our privacy risk analysis shows that Desire drastically improves privacy against malicious users (i.e., limitation of decentralized systems) and authority (i.e., limitation of centralised systems). We implemented Desire, evaluated it in real condition, and show it feasibility
Antidiabetic Medication Utilisation before and during Pregnancy in Switzerland between 2012 and 2019: An Administrative Claim Database from the MAMA Cohort.
BACKGROUND
The incidence of diabetes mellitus (both pregestational and gestational) is increasing worldwide, and hyperglycemia during pregnancy is associated with adverse pregnancy outcomes. Evidence on the safety and efficacy of metformin during pregnancy has accumulated resulting in an increase in its prescription in many reports.
AIMS
We aimed to determine the prevalence of antidiabetic drug use (insulins and blood glucose-lowering drugs) before and during pregnancy in Switzerland and the changes therein during pregnancy and over time.
METHODS
We conducted a descriptive study using Swiss health insurance claims (2012-2019). We established the MAMA cohort by identifying deliveries and estimating the last menstrual period. We identified claims for any antidiabetic medication (ADM), insulins, blood glucose-lowering drugs, and individual substances within each class. We defined three groups of pattern use based on timing of dispensation: (1) dispensation of at least one ADM in the prepregnancy period and in or after trimester 2 (T2) (pregestational diabetes); (2) dispensation for the first time in or after T2 (GDM); and (3) dispensation in the prepregnancy period and no dispensation in or after T2 (discontinuers). Within the pregestational diabetes group, we further defined continuers (dispensation for the same group of ADM) and switchers (different ADM group dispensed in the prepregnancy period and in or after T2).
RESULTS
MAMA included 104,098 deliveries with a mean maternal age at delivery of 31.7. Antidiabetic dispensations among pregnancies with pregestational and gestational diabetes increased over time. Insulin was the most dispensed medication for both diseases. Between 2017 and 2019, less than 10% of pregnancies treated for pregestational diabetes continued metformin rather than switching to insulin. Metformin was offered to less than 2% of pregnancies to treat gestational diabetes (2017-2019).
CONCLUSION
Despite its position in the guidelines and the attractive alternative that metformin represents to patients who may encounter barriers with insulin therapy, there was reluctance to prescribe it
Evolution of National Guidelines on Medicines Used to Treat COVID-19 in Pregnancy in 2020-2022: A Scoping Review.
The lack of inclusion of pregnant women in clinical trials evaluating the effectiveness of medicines to treat COVID-19 has made it difficult to establish evidence-based treatment guidelines for pregnant women. Our aim was to provide a review of the evolution and updates of the national guidelines on medicines used in pregnant women with COVID-19 published by the obstetrician and gynecologists' societies in thirteen countries in 2020-2022. Based on the results of the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial, the national societies successively recommended against prescribing hydroxychloroquine, lopinavir-ritonavir and azithromycin. Guidelines for remdesivir differed completely between countries, from compassionate or conditional use to recommendation against. Nirmatrelvir-ritonavir was authorized in Australia and the UK only in research settings and was no longer recommended in the UK at the end of 2022. After initial reluctance to use corticosteroids, the results of the RECOVERY trial have enabled the recommendation of dexamethasone in case of severe COVID-19 since mid-2020. Some societies recommended prescribing tocilizumab to pregnant patients with hypoxia and systemic inflammation from June 2021. Anti-SARS-CoV-2 monoclonal antibodies were authorized at the end of 2021 with conditional use in some countries, and then no longer recommended in Belgium and the USA at the end of 2022. The gradual convergence of the recommendations, although delayed compared to the general population, highlights the importance of the inclusion of pregnant women in clinical trials and of international collaboration to improve the pharmacological treatment of pregnant women with COVID-19
COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort
AIM
The objective of this study was to describe the use of COVID-19-related medicines during pregnancy and their evolution between the early/late periods of the pandemic.
METHODS
Pregnant women who tested positive for SARS-CoV-2 from March 2020 to July 2021 were included using the COVI-PREG registry. Exposure to the following COVID-19-related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti-interleukin-6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID-19 severity level and early/late period of the pandemic (before and after 1 July 2020).
FINDINGS
We included 1964 pregnant patients who tested positive for SARS-CoV-2. Overall, 10.4% (205/1964) received at least one COVID-19-related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti-interleukin-6 (0.3%; 5/1964). The use of at least one COVID-19-related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID-19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period.
CONCLUSION
Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID-19-related medicines in pregnancy
- …